Literature DB >> 18439681

The effect of topical bevacizumab on corneal neovascularization.

Sang Woo Kim1, Byung Jin Ha, Eung Kweon Kim, Hungwon Tchah, Tae-im Kim.   

Abstract

PURPOSE: To examine the effect of topical bevacizumab on corneal neovascularization (NV) over a period of 3 months.
DESIGN: Prospective, nonrandomized, masked observational case series. PARTICIPANTS: Ten eyes of 7 patients with corneal NV.
METHODS: Patients received topical bevacizumab (1.25%) twice daily. Ophthalmic evaluations included visual acuity, slit-lamp examination, and tonometry. MAIN OUTCOME MEASURES: Corneal NV and changes in ophthalmic evaluations.
RESULTS: Decreased corneal NV was noted in 7 of 10 eyes, usually within 1 month of treatment. Epitheliopathy (epithelial defect, epithelial erosion) was observed in 6 of 10 eyes, 1 resulting in corneal thinning. Adverse effects generally appeared during the second month of treatment.
CONCLUSIONS: Topical application of bevacizumab was effective in reducing corneal NV within the first month. However, by the second month there was an increased risk of adverse effects.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18439681     DOI: 10.1016/j.ophtha.2008.02.013

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  67 in total

1.  Three-year corneal graft survival rate in high-risk cases treated with subconjunctival and topical bevacizumab.

Authors:  Iva Dekaris; Nikica Gabrić; Nataša Drača; Maja Pauk-Gulić; Neven Miličić
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-11-16       Impact factor: 3.117

Review 2.  Emerging techniques to treat corneal neovascularisation.

Authors:  J Menzel-Severing
Journal:  Eye (Lond)       Date:  2011-10-07       Impact factor: 3.775

3.  [Pterygium. Etiology, clinical aspects and novel adjuvant therapies].

Authors:  L M Heindl; C Cursiefen
Journal:  Ophthalmologe       Date:  2010-06       Impact factor: 1.059

4.  Curcumin nanoparticles inhibit corneal neovascularization.

Authors:  Nirparaj Pradhan; Rajdeep Guha; Sushovan Chowdhury; Sudip Nandi; Aditya Konar; Sarbani Hazra
Journal:  J Mol Med (Berl)       Date:  2015-04-17       Impact factor: 4.599

5.  Corneal penetration of topical and subconjunctival bevacizumab.

Authors:  Mohammad H Dastjerdi; Zahra Sadrai; Daniel R Saban; Qiang Zhang; Reza Dana
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-11-07       Impact factor: 4.799

Review 6.  [Topical inhibition of angiogenesis at the cornea. Safety and efficacy].

Authors:  B Regenfuss; F Bock; B Bachmann; Y König; D Hos; A Parthasarathy; C Cursiefen
Journal:  Ophthalmologe       Date:  2009-05       Impact factor: 1.059

Review 7.  Current and emerging therapies for corneal neovascularization.

Authors:  Danial Roshandel; Medi Eslani; Alireza Baradaran-Rafii; Albert Y Cheung; Khaliq Kurji; Sayena Jabbehdari; Alejandra Maiz; Setareh Jalali; Ali R Djalilian; Edward J Holland
Journal:  Ocul Surf       Date:  2018-06-20       Impact factor: 5.033

Review 8.  Corneal nerves in health and disease.

Authors:  Brittany Simmons Shaheen; May Bakir; Sandeep Jain
Journal:  Surv Ophthalmol       Date:  2014-01-23       Impact factor: 6.048

9.  Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization.

Authors:  Olga Dratviman-Storobinsky; Bat-Chen R Avraham-Lubin; Murat Hasanreisoglu; Nitza Goldenberg-Cohen
Journal:  Mol Vis       Date:  2009-11-13       Impact factor: 2.367

10.  One-year follow-up of epithelial corneal cell sheet allografts mounted on platelet poor plasma in rabbits.

Authors:  Federico Luengo Gimeno; Victoria Lavigne; Silvia Gatto; J Oscar Croxatto; Laura Correa; Juan E Gallo
Journal:  Mol Vis       Date:  2009-12-15       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.